Blerina Resuli: New Insights on the Adoption of Immunotherapy in Lung Cancer Care in Germany
Blerina Resuli, LMU University Hospital Munich at Consultant Clinical Oncologist, Thoracic Oncology, shared a post on LinkedIn:
“New insights on the adoption of immunotherapy in lung cancer care in Germany.
We are excited to share our recent study, published in BMC Public Health, analyzing prescribing patterns and access to immune checkpoint inhibitors (ICIs) in over 9,700 German patients with advanced lung cancer. PD Dr. med. Diego Kauffmann-Guerrero
Key findings:
• ICI uptake was initially slow, increasing from 1.1% (early 2017) to 8.6% (end of 2019).
• Access was higher among younger patients, those with COPD, and those treated in larger hospitals.
• A more recent year of diagnosis was associated with faster adoption.
Conclusion: To ensure equitable access, dissemination of innovations and support for smaller healthcare facilities are essential.”
Title: Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis
Authors: Julia Walter, Blerina Resuli, Laura Sellmer, Diego Kauffmann-Guerrero, Toki Bolt, Chukwuka Eze, Jürgen Behr, and Amanda Tufman
Read The Full Article at BMC Public Health.
More Posts Featuring Immunotherapy.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023